SMMT Summit Therapeutics Inc

Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and Clostridium difficile infection, will host a Utrophin R&D Day featuring presentations from three DMD key opinion leaders alongside Summit’s management on 15 June 2016 in New York City.

This event is open to analysts, institutional investors and members of the press. For more information, email investors@summitplc.com.

A live audio webcast of the presentation will be available through the Investors section on the Company’s website, www.summitplc.com. A replay of the webcast will be available soon after the live presentation.

About Summit Therapeutics Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

Summit Therapeutics Glyn Edwards / Richard Pye (UK office)Erik Ostrowski / Michelle Avery (US office)	Tel: +44 (0)1235 443 951  +1 617 225 4455
Cairn Financial Advisers LLP (Nominated Adviser)Liam Murray / Tony Rawlinson	Tel: +44 (0)20 7148 7900
N+1 Singer (Broker)Aubrey Powell / Jen Boorer	Tel: +44 (0)20 7496 3000
MacDougall Biomedical Communications(US media contact)Chris Erdman / Karen Sharma	Tel: +1 781 235 3060 cerdman@macbiocom.com / ksharma@macbiocom.com
Consilium Strategic Communications (Financial public relations, UK)Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / Lindsey Neville	Tel: +44 (0)20 3709 5700summit@consilium-comms.com

-END-